Intrabeam; an innovative treatment which considerably increases the chance of complete recovery of patients with early stage breast cancer
Intrabeam intraoperative radiotherapy (IORT) is a new treatment method which provides the physician an extra possibility to irradiate local and focused subsequent to the surgical procedure. The system is freely placeable in the operating room. Irradiation is carried out using a sterile fine probe, which is inserted directly into the wound.
The treatment effectively kills cancer cells which remain after the complete or partial tumor removal. This reduces the chance of a recurrence significantly.
Advantages patient Intrabeam intraoperative radiotherapy (IORT)
Intrabeam is directly applied during surgery and destroys any remaining cancer cells immediately after the removal of the primary tumor mass. The intraoperative radiotherapy technique has a maximum precision, acting directly on the surgical area boundaries and minimizes the negative effects of radiation on healthy tissue (max. 2 cm).
Intra-operative radiotherapy (kV) with a low energy is an excellent alternative to external radiation (MV). A combination is also possible. It is less stressful for the patient and provides better prognosis.
External irradiation to effect cancer cells has also a deleterious effect on healthy tissue. Radiotherapy applied right after surgery can slow the healing of wounds and can cause numerous postoperative complications. Therefore, it is recommended to start external radiation one month after the surgery. By that time, the risk of resumption of the malignant process increases.
Compatibility of intraoperative radiotherapy with other forms of cancer treatments
Intraoperative radiotherapy with Intrabeam is very well combinable with chemotherapy and other therapies. The application of IORT as ‘boost’ therapy ahead of external radiotherapy also gives very good results. The delivered dose right after the surgery ensures there is less dose required in the subsequent external beam radiation. This reduces local and systematic side effects.
- breast cancer (TARGIT)
- spinal metastases (Kypho-IORT)
- skin cancer (electronic brachytherapy)
- gastrointestinal tumors (Gastro-IORT)
- Intrabeam IORT media page
- Intrabeam worldwide newsflash
- TARGIT: review of clinical evidence for breast cancer – Why Intrabeam in breast cancer?
- Intraoperatief radiotherapie systeem Intrabeam
Looking for a solution? Discuss it with PEO.
Stay informed about product news, which is related to your field of expertise. Go to the PEO news sign up form and select your areas of interest.